Migraine drug delay would compound Teva's troubles

Migraine drug delay would compound Teva's troubles


TEL AVIV: Teva Pharmaceutical Industries is counting on its new migraine treatment to haul it out of the doldrums. But a possible delay in U.S. approval and looming pricing battle are making the task harder.



from Biotech News